Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BIMERVAX Coadministered with Adjuvanted Influenza Vaccine (SIIV) in Older Adults
NCT05981846Phase 2Completed
- Sponsor
- HIPRA
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BIMERVAX + SIIV, BIMERVAX + Placebo and SIIV + Placebo (3 arms). Primary endpoints: Number, percentage, and characteristics of solicited local and systemic reactions at Day 7, Number, percentage, and characteristics of unsolicited local and systemic adverse events at Day 28 and 2 more. Started Sep 2023; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05981846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981846.